Related Experiment Videos
Growth factor receptors and oncogene expression in prostate cells
P Davies1, C L Eaton, T D France
1Tenovus Institute for Cancer Research, University of Wales College of Medicine, Cardiff.
American Journal of Clinical Oncology
|January 1, 1988
Summary
Prostate cancer cells show altered growth factor receptor expression and protooncogene activity. These changes, including increased epidermal growth factor (EGF) receptors and c-myc, may indicate disease progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Benign prostatic hypertrophy (BPH) and prostate carcinoma exhibit distinct cellular characteristics.
- Understanding receptor expression and protooncogene activity in prostate cancer is crucial for identifying progression markers.
Purpose of the Study:
- To investigate the binding capacity of androgens, radioiodinated EGF, and IGF-I in BPH and prostate carcinoma.
- To assess the expression of cellular protooncogenes in these prostate conditions.
Main Methods:
- Analysis of human prostate tissue specimens (BPH and carcinoma) and cultured prostate cells.
- Measurement of androgen, EGF, and IGF-I receptor binding.
- Quantification of protooncogene expression (c-myc, c-fos, c-H-ras).
Main Results:
- Prostate cell lines and diseased prostate tissues possess receptors for EGF and IGF-I.
- Prostate carcinoma showed higher EGF receptor concentrations than BPH.
- Increased EGF receptors correlated with decreased androgen receptors, poorer differentiation, and elevated c-myc expression.
- Deteriorating differentiation was linked to changes in IGF-I binding and increased c-H-ras expression.
Conclusions:
- Alterations in EGF and IGF-I receptor expression and protooncogene activity are observed in prostate cancer.
- These molecular changes may serve as indicators of prostate cancer progression.
- Further validation in cell lines is recommended to confirm these findings.